NIVF Stock Analysis: Buy, Sell, or Hold?
NIVF - NewGenIvf Group Limited Class A ordinary shares
$1.26
-0.23 (-15.44%)
▼
5d:
+142.91%
30d:
+83.94%
90d:
-40.85%
WAIT
LOW Confidence
Analysis Updated: Jul 6, 2026 12:00 AM ET
Earnings: Jun 30, 2026
0d
Get Alerted When NIVF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called NIVF this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NIVF is 51.8% above its trading range ($0.83). Market expects 1.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NIVF is 51.8% above its trading range ($0.83). Market expects 1.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.64
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$2.26
44.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NIVF is currently trading at $1.26, which is considered oversold relative to its 30-day fair value range of $0.52 to $0.83. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.2) compared to its historical average (0.2). At these levels, the market is pricing in 1.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NIVF is in a uptrend. The price is approaching resistance at $1.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 15.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.12 (+847.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NIVF is in a uptrend. The price is approaching resistance at $1.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 15.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.12 (+847.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.52 -
$0.83
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-15.4%)
- BULLISH: Trading 847.7% below Wall St target ($14.12)
- BULLISH: Market expects only 1.9% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to 51.8% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.52 -
$0.83
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.47
Resistance Level
$1.20
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.16
Wall Street Target
$14.12
(+847.7%)
Revenue Growth (YoY)
11.9%
Profit Margin
209.0%
Valuation Premium vs History
+1.9% premium
PE vs Historical
0.2 vs 0.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.9%
(market-implied from PE analysis)
1-Year Target
$1.52
(+2%)
2-Year Target
$1.55
(+4%)
3-Year Target
$1.58
(+6%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$1.98
(+33%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 97.0%)
$686.56
(+45978%)
Base:
(SPY PE: 0.2, Growth: 97.0%)
$5.03
(+238%)
Bear:
(PE: 0.1, Growth: 97.0%)
$4.27
(+187%)
📈
Valuation based on Current Earnings
Trailing PE: 0.00 | Current EPS (TTM): $109.68
Bull Case
$0.25
(-83%)
Analyst growth -50.0%, PE expands to 0.0
Base Case
$0.23
(-85%)
Market implied -50.0%, PE stable at 0.0
Bear Case
$0.31
(-79%)
Severe decline -20.0%, PE contracts to 0.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 07, 2026 11:49 AM ET
Data refreshes hourly during market hours. Next update: 12:49 PM
Data refreshes hourly during market hours. Next update: 12:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NIVF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$243 | 56 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$500 | 66 BUY |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$141 | 58 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$22 | 53 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$133 | 60 HOLD |
